The Effect of Maximum Body Weight in Lifetime on the Development of Type 2 Diabetes (MAXWEL)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Soo Lim, Seoul National University Bundang Hospital
ClinicalTrials.gov Identifier:
NCT00816608
First received: December 31, 2008
Last updated: October 24, 2013
Last verified: October 2013
  Purpose

Hypothesis : The maximum body weight in lifetime is associated with the onset of development of type 2 diabetes.


Condition
Diabetes
Prediabetes

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Study of MAXimum Weight in Lifetime on Glucose Homeostasis (MAXWEL)

Resource links provided by NLM:


Further study details as provided by Seoul National University Bundang Hospital:

Primary Outcome Measures:
  • The development of diabetes [ Time Frame: Five years ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • DM complication [ Time Frame: 5 years ] [ Designated as safety issue: No ]

Enrollment: 3000
Study Start Date: August 2006
Study Completion Date: September 2013
Primary Completion Date: December 2012 (Final data collection date for primary outcome measure)
Groups/Cohorts
type 2 diabetes

Detailed Description:

Obesity is well recognized risk factor for type 2 diabetes. Recent studies reported that weight change, especially severe weight gain was associated with an increased risk of type 2 diabetes. The aim of this study is to investigate whether the maximum body weight of lifetime is associated with the early onset of type 2 diabetes or an increased risk of type 2 diabetes in Korean.

  Eligibility

Ages Eligible for Study:   20 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Korean with type 2 diabetes Korean with confirmed IFG or IGT Korean with NGT

Criteria

Inclusion Criteria:

  • Korean with type 2 diabetes
  • Korean with confirmed IFG or IGT
  • Korean with NGT

Exclusion Criteria:

  • Malignancy except thyroid cancer
  • Active tuberculosis
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00816608

Locations
Korea, Republic of
Seoul National University Bundang Hospital
Seongnam, Bundang-gu, Korea, Republic of, 463-707
Sponsors and Collaborators
Seoul National University Bundang Hospital
Investigators
Principal Investigator: Soo Lim Seoul National University Bundang Hospital
  More Information

No publications provided

Responsible Party: Soo Lim, Professor, Seoul National University Bundang Hospital
ClinicalTrials.gov Identifier: NCT00816608     History of Changes
Other Study ID Numbers: MAXWEL 09
Study First Received: December 31, 2008
Last Updated: October 24, 2013
Health Authority: Korea: Food and Drug Administration

Keywords provided by Seoul National University Bundang Hospital:
diabetes
prediabetes
impaired fasting glucose (IFG)
impaired glucose tolerance (IGT)
body weight

Additional relevant MeSH terms:
Glucose Intolerance
Prediabetic State
Diabetes Mellitus
Hyperglycemia
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases

ClinicalTrials.gov processed this record on October 19, 2014